Publications listings

E McFadden; 2016

Data Management and Coordination

Wiley StatsRef: Statistics Reference online, 1-14 doi:10.1002/9781118445112.stat04933.pub2,

I Gingras; E Holmes; E. de Azambuja; D H A Nguyen; M Izquierdo; J A Zujewski; M Inbar; B Naume; G Tomasello; J Gralow; AC Wolff; L Harris; M Gnant; A Moreno-Aspitia; M. Piccart; H. A. Azim Jr; 2017

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis from the ALTTO Trial

Journal of the National Cancer Institute, Volume 109, Issue 8, doi: 10.1093/jnci/djw331,

W Shi; T Jiang; P Nuciforo; C Hatzis; E Holmes; N Harbeck; C Sotiriou; L Peña; S Loi; D Rosa; S Chia; A Wardley; T Ueno; J Rossari; H. Eidtmann; A Armour; M Piccart-Gebhart; D L Rimm; J Baselga; L Pusztai; 2017

Pathway level alterations rather than mutations in single genes predict response to HER2 targeted therapies in the neo-ALTTO trial

Annals of Oncology, Volume 28, Issue 1, p128-135, doi:10.1093/annonc/mdw434,

D Cameron; M Piccart-Gebhart; RD Gelber; M Procter; A Goldhirsch; E. de Azambuja; G Castro Jr; M Untch; I Smith; L Gianni; J Baselga; N Al-Sakaff; S Laver; E McFadden; B Leyland-Jones; R Bell; M Dowsett; C Jackisch; March 25, 2017

11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

www.thelancet.com, Volume 389, Issue 10075, pp. 1195-1205, doi:10.1016/S0140-6736(16)32616-2,

S Di Cosimo; C Campbell; H A Hazim; G Curigliano; R Crescenzo; L de la Pena; M Piccart-Gebhart; H. Eidtmann; J Baselga; E. de Azambuja; 2016

Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06)

Cancer Research, Volume 76, Issue 4, doi:10.1158/1538-7445.SABCS15-P6-01-04,

E McFadden; S Bashir; S Canham; J Darbyshire; P Davidson; S Day; S Emery; J Pater; S Rudkin; M Stead; J Brown; 2015

The impact of registration of clinical trials units: the UK experience

Clinical Trials, Volume 12, Issue 2, Pages 166-173, doi:10.1177/1740774514561242 ,

O Metzger-Filho; E. de Azambuja; M Procter; M Krieguer; I Smith; J Baselga; D Cameron; M Untch; C Jackisch; R Bell; L Gianni; A Goldhirsch; M. Piccart; RD Gelber; HERA Study Team; 2016

Trastuzumab Re-Treatment Following Adjuvant Trastuzumab and the Importance of Distant Disease-Free Interval: the HERA Trial Experience

Breast Cancer Research and Treatment, Volume 155, Issue 1, Pages 127-132,doi: 10.1007%2Fs10549-015-3656-0,

A Goldhirsch; RD Gelber; M Piccart-Gebhart; E. de Azambuja; M Procter; T M Suter; C Jackisch; H A Weber; D Heinzmann; L D Lago; E McFadden; M Dowsett; M Untch; L Gianni; R Bell; A Vindevoghel; M Andersson; C Köhne; D Cameron; 2013

2 Years Versus 1 Year of Adjuvant Trastuzumab for HER2-Positive Breast Cancer (HERA): an Open-Label, Randomised Controlled Trial

The Lancet, Volume 382, Issue 9897, Pages 1021-1028, doi: 10.1016/S0140-6736(13)61094-6,

O Metzger-Filho; M Procter; E. de Azambuja; B Leyland-Jones; RD Gelber; M Dowsett; S Loi; K S Saini; D Cameron; M Untch; I Smith; L Gianni; J Baselga; C Jackisch; R Bell; C Sotiriou; G Viale; M Piccart-Gebhart; 2013

Magnitude of Trastuzumab benefit in patients with HER2 positive, invasive lobular breast carcinoma: results from the HERA trial

Journal of Clinical Oncology, Volume 31, Issue 16, Pages 1954-1960, doi: 10.1200/JCO.2012.46.2440,

L Gianni; U Dafni; RD Gelber; E. de Azambuja; S Muehlbauer; A Goldhirsch; M Untch; I Smith; J Baselga; C Jackisch; D Cameron; M Mano; J Luiz Pedrini; A Veronesi; C Mendiola; A Pluzanska; V Semiglazov; E Vrdoljak; M J Eckart; Z Shen; G Skiadopoulos; M Procter; KI Pritchard; R Bell; 2011

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow up of randomized controlled trail

The Lancet, Volume 12, Issue 3, Pages 236-244, doi: 10.1016/S1470-2045(11)70033-X,